Presentation is loading. Please wait.

Presentation is loading. Please wait.

Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment  Sven O Friedrich,

Similar presentations


Presentation on theme: "Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment  Sven O Friedrich,"— Presentation transcript:

1 Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment  Sven O Friedrich, PhD, Andrea Rachow, MD, Elmar Saathoff, PhD, Kasha Singh, MD, Chacha D Mangu, MD, Prof Rodney Dawson, MD, Patrick PJ Phillips, PhD, Amour Venter, NatDipMicro, Anna Bateson, PhD, Catharina C Boehme, MD, Norbert Heinrich, MD, Robert D Hunt, PhD, Martin J Boeree, MD, Prof Alimuddin Zumla, FRCP, Prof Timothy D McHugh, PhD, Prof Stephen H Gillespie, FRCP, Prof Andreas H Diacon, MD, Prof Michael Hoelscher, FRCP  The Lancet Respiratory Medicine  Volume 1, Issue 6, Pages (August 2013) DOI: /S (13)70119-X Copyright © 2013 Elsevier Ltd Terms and Conditions

2 Figure 1 Qualitative data for all tests at baseline and follow-up visits The Lancet Respiratory Medicine 2013 1, DOI: ( /S (13)70119-X) Copyright © 2013 Elsevier Ltd Terms and Conditions

3 Figure 2 Increase in CTmin during tuberculosis treatment fitted with three different statistical models Note break in y axis. The horizontal line is the positivity cutoff value. CTmin=minimal cycle threshold. The Lancet Respiratory Medicine 2013 1, DOI: ( /S (13)70119-X) Copyright © 2013 Elsevier Ltd Terms and Conditions


Download ppt "Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment  Sven O Friedrich,"

Similar presentations


Ads by Google